Johnson & Johnson has completed its previously announced divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.

The Cordis business develops and manufactures interventional vascular technology and generated net revenues of approximately $780 million in 2014.

Source: Johnson & Johnson